Natco Pharma Ltd (Natco Pharma) is a research-focused pharmaceutical company engaged in the development, manufacturing, and marketing of Finished Dosage Formulations (FDFs), Active Pharmaceutical Ingredients (APIs), and Agrochemicals. The company has a diverse portfolio that covers the entire value chain, from developing and manufacturing APIs and FDFs to successfully commercializing them in both domestic and international markets. Natco Pharma has nine manufacturing facilities and research centers across India including 5 FDF manufacturing facilities, 2 API manufacturing facilities and 2 crop health sciences units.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Natco Pharma's R&D arm focuses on advancing scientific capabilities, expanding technology platforms, and enabling complex therapeutic programs. The company is investing in oligonucleotide and peptide development, novel drug delivery systems, and cell and gene therapy platforms. It is also involved in developing complex drug delivery formulations and addressing formulation challenges associated with poorly soluble drugs. The company is committed to advancing diabetes care and making treatments for conditions like Spinal Muscular Atrophy more accessible and affordable. Strategic investments in scientific talent, specialized infrastructure, and integrated development expertise are key components of the company's R&D strategy. The R&D units of Natco Pharma include the Pharma Research & Development division, which focuses on being first-to-market and fast-to-market with new product development. The Analytical R&D (ARD) supports API and formulations development for generics and new chemical entities (NCEs). The Novel Drug Delivery Systems (NDDS) division at NATCO Research Centre (NRC) develops complex drug delivery formulations. The Agro Research & Development unit, NATCO Crop Health Sciences R&D Centre, focuses on crop protection solutions and sustainable agriculture. Natco Pharma 2 world-class R&D centers. In FY2026, the company filed 329 international patents and 299 Indian patents, and has been granted 217 international patents and 116 Indian patents. The pipeline includes 116 Para IVs with over 20 first-to-file (FTF) products. Its major technology alliances include investments in eGenesis for xenotransplantation, Cellogen Therapeutics for CAR-T cell therapies, and Stero Therapeutics for novel therapies for metabolic diseases. In FY2026, the company spent INR4,086 million on its R&D activities, which as a percentage of revenue stood at 9.3%.